ClinicalTrials.Veeva

Menu

Macrophage Programing in Acute Lung Injury

National Jewish Health logo

National Jewish Health

Status

Unknown

Conditions

Acute Respiratory Distress Syndrome

Treatments

Procedure: Mini bal

Study type

Observational

Funder types

Other

Identifiers

NCT03844893
HS-3076

Details and patient eligibility

About

The histologic hallmarks of lung inflammation and in the extreme, acute respiratory distress syndrome (ARDS), include intense accumulation of inflammatory cells in the airspaces and interstitium, injury to alveolar epithelial and endothelial cells, loss of epithelial-capillary integrity and accumulation of edema fluid in the interstitium and airspaces. Accordingly, for alveolar repair to occur inflammation must be halted, debris and inflammatory cells removed, injured tissue cells replaced, and capillary barrier function re-established. Macrophages are key players in all of these. Here the investigators hypothesize that resident alveolar macrophages and recruited macrophages serve completely different functions, acting independently (i.e. division of labor) yet cooperatively (synergism).

Enrollment

56 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Written, informed consent (by surrogate if unconscious or if altered mental status)
  2. Admission to a Medical Intensive care unit
  3. Orally/nasally intubated, evaluable within 24 h of intubation or onset of ARDS
  4. Expected to remain mechanically ventilated for at least 48 h after the first study procedure.

Exclusion criteria

  1. Treatment with immunosuppressants in the prior 3 months (antineoplastic agents, tumor necrosis factor alpha antagonists, cyclosporine, methotrexate, azathioprine, or mycophenolate. Treatment with glucocorticoids for septic shock is acceptable).
  2. History of solid organ or bone marrow transplantation
  3. History of chronic lung disease (e.g. COPD, pulmonary fibrosis, cystic fibrosis)
  4. Human immunodeficiency virus positivity
  5. Severe or massive hemoptysis
  6. At significant risk for bleeding (INR > 3 or PTT > 3x normal)
  7. Presence of an advanced directive to withhold life-sustaining treatment
  8. Morbid state or expected to survive less than 14 days because of an advanced co-morbid medical condition;
  9. Pregnancy

Trial contacts and locations

0

Loading...

Central trial contact

Christine Griesmer, MPH

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems